Wells Fargo resumed coverage on Arcturus Therapeutics with a new price target
$ARCT
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo resumed coverage of Arcturus Therapeutics with a rating of Overweight and set a new price target of $35.00